The association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery

DA-ZHONG CAO, XI-LONG OU and TING YU

Department of Gastroenterology, The Affiliated ZhongDa Hospital of Southeast University, Nanjing, Jiangsu 210009, P.R. China

Received September 1, 2015; Accepted January 4, 2017

DOI: 10.3892/ol.2017.5929

Abstract. The present study aimed to examine the association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery. The present study included 484 patients with colon cancer that underwent colon resection between December 2003 and December 2011. All follow-ups were censored in December 2013 with a median follow-up time of 43 months. Kaplan-Meier survival curves and Cox regression analysis were used to determine predictors for overall survival rate. p53 expression status (positive or negative) was significantly different between patient groups when categorized by age distribution, disease course, tumor location, maximum tumor diameter, depth of tumor invasion, Dukes’ stage, distant metastasis and lymph node (LN) metastasis (P<0.05). Cox regression analysis revealed that age, surgery type, histological subtypes, tumor size, tumor location, LN metastasis, distant metastases, Dukes’ stage and p53 expression status are independent factors influencing the survival rate of patients with colon cancer following surgery (P<0.05). Therefore, the present study revealed that the loss of p53 expression levels in tumors was associated with aggressive clinicopathological characteristics in patients with colon cancer.

Introduction

Colorectal cancer (CRC) or colon cancer, is the third most frequently diagnosed type of cancer in males, the second in females and the fourth most frequent cause of cancer mortality (1,2). In 2012, it was estimated that 1,360,602 million new cases (women, 614,304; men, 746,298) of CRC were diagnosed (3). The burden of CRC worldwide is expected to increase by 60% to >2.2 million new cases and 1.1 million CRC-associated mortalities by 2030 (4). The curative or palliative treatment for colon cancer is dependent on various factors, including the patient’s health and tumor stage, and curative surgery is typically recommended if colon cancer is diagnosed early and palliative care is provided for advanced colon cancer (5,6). The U.S. National Comprehensive Cancer Network and American Society of Clinical Oncology have provided guidelines for the recommended follow-up of colon cancer (7,8) and have identified that surveillance and detailed follow-up following curative resection of colon cancer may reduce the 5-year mortality rate and improve overall survival (OS) and the re-resection rate for recurrent disease (9-11). However, complications from surgery still occur frequently, resulting in an average length of hospital stay of 8-12 days subsequent to a standard colon resection and, therefore, the risk factors following colectomy for colon cancer require further investigation (12,13).

The prognosis of patients with colon cancer is dependent on clinical, pathological and biological factors, including age (14), gender, Dukes’ stage (15), quantity of blood loss during surgery (16), lymph node (LN) invasion, bowel wall penetration, invasive margin character and type of tumor, and these may be effective prognostic indicators for predicting the survival rate of patients with colon cancer following surgery (17-20). In addition, patients with tumor perforation or incomplete resection have a poor prognosis following curative resection of Dukes’ B colon cancer (21). In previous studies, p53 protein expression levels have been established to predict the outcome of Dukes’ stage B CRC (22) and the p53 status may provide an effective prognostic factor for patients with Dukes’ B and C colon cancer (23). The p53 tumor suppressor protein (encoded by TP53) is involved in DNA damage repair, cell cycle regulation, apoptosis, aging and cellular senescence and is mutated in ~50% of types of cancer (24). Additionally, p53 overexpression is associated with a reduced survival rate in patients with stage III tumors and p53 expression levels are able to predict CRC biology and clinical behavior (25,26). Using multivariate analysis, a p53 codon 72 mutation, a
mutation hotspot identified in Egyptian populations, has been suggested to be an independent prognostic factor for disease-free survival (DFS) in patients with colon cancer from this geographical region (27). In addition, p53 overexpression was an independent predictor of tumor recurrence in patients with colon cancer (28) and increased nuclear p53 expression levels were associated with the presence of distal metastasis in stage II colon cancer (29). p53 immunoreactivity was implicated to be closely associated with clinicopathological variables, including pathological type, lymphocytic infiltration, tumor grade and the tumor site in CRC (30). The p53 functional status was demonstrated to provide a prognostic marker for patients with colon cancer (31); however, a previous study did not identify a significant association between p53 and DFS or OS in patients with locally advanced colon cancer (32). The prognosis of patients with colon cancer is primarily dependent on standard clinicopathological factors. In the present study, the association of p53 expression levels with clinicopathological features and prognosis was investigated to evaluate their prognostic value in patients with colon cancer following surgery.

Materials and methods

Study design and subjects. Between December 2003 and December 2011, 484 patients with primary colon cancer were enrolled onto the present study at the Department of Gastroenterology, The Affiliated ZhongDa Hospital of Southeast University (Nanjing, China). The inclusion criteria were as follows: i) Patients that underwent radical and palliative surgery for colon cancer treatment; ii) patients with a pathologically confirmed colon cancer diagnosis; and iii) patients with complete follow-up data. The exclusion criteria were as follows: i) Patients who had preoperative chemotherapy or radiotherapy; and ii) patients with pathologically positive margins. The patients were composed of 296 males and 188 females with an average age of 61.94 years (range, 25-88). The age distribution was categorized as <40 (n=63), 40-60 (n=226) and >60 years (n=195). There were 58 cases with Dukes’ A colon cancer, 189 cases with Dukes’ B colon cancer, 201 cases with Dukes’ C colon cancer and 36 cases with Dukes’ D colon cancer according to the revised Dukes’ staging (33). The types of tissue samples included 210 mass samples, 183 ulceration samples and 91 invasion samples.

Following approval from the Affiliated ZhongDa Hospital of Southeast University, written informed consent was obtained from all patients. Protocols of the present study were based on the ethical principles of The Declaration of Helsinki for medical research that includes human patients (34).

Immunohistochemistry. Surgically resected tumor specimens from enrolled patients were obtained and were formalin-fixed and paraffin-embedded to create tissue blocks from which 4 μm tissue sections were cut. Conventional dewaxing and hydration with a series of graded alcohol was performed. Briefly, the tissue sections were rinsed with dimethylbenzene twice (10 min/wash), followed by rinsing with a descending series of graded alcohol (100, 95, 90, 80 and 70%; 3-5 min/wash) and final 3 min rinse in distilled water. Subsequent antigen retrieval was performed using a microwave, followed by the addition of 3% hydrogen peroxide to block endogenous peroxidase activity. Primary mouse anti-human p53 antibody (DO-7; 1:100; cat. no. MAB-0674; Fuzhou Maixin Biotech Co., Ltd., Fuzhou, China) was added, and the tissue sections were incubated at 4°C overnight. Following incubation for 20 min, the sections were treated with horseradish peroxidase-labeled goat anti-mouse secondary antibody (1:1,000; cat. no. ab6785; Abcam, Cambridge, MA, USA) for 30 min at room temperature. The immunohistochemistry analysis was performed using an SP ultrasensitive immunostaining kit according to the manufacturer’s protocol, followed by DAB for visualization (both Fuzhou Maixin Biotech Co., Ltd.). The replacement of the primary antibody with PBS was used as a negative control. As a positive control, tissue sections that were positively stained for p53 were included in each staining run (Fuzhou Maixin Biotech Co., Ltd.). If ≥10% of the malignant nuclei were stained, the slide was scored as positive based on the standard scoring for p53 expression status as described in a previous study (23).

Follow-up of patients with colon cancer following surgery. All patients were followed up via outpatient review, telephone calls, letters and other forms of communication. The follow-up time was measured from the date of surgery and patients were followed up semiannually during the first 2 to 5 years and annually thereafter. All follow-ups were completed by December 2013, there was a median follow-up duration of 43 months and the longest follow-up was 120 months. The survival rate was calculated from the time of surgery to the date of mortality, or date of final follow-up.

Statistical analysis. Clinical and pathological data obtained from the follow-up of patients were coded into a database using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA). Statistical analysis was performed using SPSS software (version 18.0; SPSS Inc., Chicago, IL, USA). Statistical analysis was performed using the χ2 test. Survival distributions were estimated using Kaplan-Meier survival analysis. Estimated probabilities of survival rate were compared with the log-rank method. To identify independent prognostic factors, variables that were significantly associated with the prognostic information from the univariate analysis were applied in the Cox regression model. P<0.05 was considered to indicate a statistically significant difference.

Results

Clinical characteristics. The clinical and pathological characteristics of 484 patients with colon cancer are presented in Table I. There were 96 patients (19.38%) with a disease course length of <1 month, 152 cases (31.40%) with 1-3 months, 65 cases (13.43%) with 3-6 months, 75 cases (15.50%) with 6-12 months and 96 cases (19.84%) with ≥12 months. The median disease course length was 3-6 months. The tumor location was categorized as right (cecum, ascending colon and hepatic flexure), transverse and left (splenic flexure, descending colon and sigmoid colon), and these accounted for 245 cases (50.62%), 50 cases (10.33%) and 189 cases (39.05%), respectively. With regard to the type of surgery...
that was selected, 403 cases (83.26%) had radical surgery and 81 cases (16.74%) had palliative surgery for the treatment of colon cancer. The quantities of perioperative blood transfusion that were administered to patients were 0 ml (did not have a blood transfusion) in 295 cases (60.95%), ≤400 ml in 100 cases (20.66%) and 400-800 ml in 89 cases (18.39%). A maximum tumor diameter of ≤4 cm was observed in 212 cases (43.80%), 4-8 cm in 255 cases (52.69%) and >8 cm in 17 cases (3.51%). Gross types of colon cancer tissue samples were categorized as fungating type (210 cases, 43.39%), infiltrative type (91 cases, 18.80%) and ulcerative type (183 cases, 37.81%), respectively. The histological subtypes were divided into moderately/well-differentiated adenocarcinomas (383 cases, 79.13%), poorly differentiated adenocarcinoma (43 cases, 8.89%), mucinous adenocarcinoma (49 cases, 10.12%) and signet-ring cell carcinoma (9 cases, 1.86%).

**Association of p53 expression with clinical characteristics.** As summarized in Table II, positive nuclear p53 immunoreactivity was identified in 253 patients (52.27%) and tumors from 231 patients (47.73%) were negative for p53 expression. The p53 expression status (positive or negative) was significantly different between patient subgroups when categorized according to age distribution, disease course, tumor location, surgery, perioperative blood transfusion, tumor size, histological subtypes, LN metastasis, depth of invasion, Dukes' stage, distant metastasis and LN metastasis (P<0.05). However, p53 expression levels were not statistically different between the two genders or the gross tumor type.

**Univariate survival rate analysis.** The mean OS was 79.78±3.85 months for patients with colon cancer at the time of the final follow-up. The 3-, 5- and 10-year survival rates were 68.02, 59.70 and 52.27%, respectively. The univariate analysis (Table III) revealed that age, course of disease, tumor location, surgery, perioperative blood transfusion, tumor size, histological subtypes, LN metastasis, depth of invasion, distant metastasis, Dukes' stage and p53 protein expression status were significantly associated with postoperative survival rate in patients with colon cancer (P<0.05). Statistical associations were not detected between gender and gross tumor type.

**Multivariate survival rate analysis.** In the multivariate analysis, age, surgery, histological subtypes, tumor size, tumor

| Characteristics                  | Number of patients (%) |
|----------------------------------|------------------------|
| Gender                           |                        |
| Male                             | 296 (61.16)            |
| Female                           | 188 (38.84)            |
| Age, years                       |                        |
| <40                              | 63 (13.02)             |
| 40-60                            | 226 (46.69)            |
| >60                              | 195 (40.29)            |
| Time course of disease, months   |                        |
| <1                               | 96 (19.83)             |
| 1-3                              | 152 (31.40)            |
| 3-6                              | 65 (13.43)             |
| 6-12                             | 75 (15.50)             |
| ≥12                              | 96 (19.84)             |
| Tumor location                   |                        |
| Left hemicolon                   | 245 (50.62)            |
| Colon transversum                | 50 (10.33)             |
| Right hemicolon                  | 189 (39.05)            |
| Surgery                          |                        |
| Radical surgery                  | 403 (83.26)            |
| Palliative surgery               | 81 (16.74)             |
| Perioperative blood transfusion, ml|                      |
| 0                                | 295 (60.95)            |
| ≤400                             | 100 (20.66)            |
| 400-800                          | 89 (18.39)             |
| Tumor size, cm                   |                        |
| ≤4                               | 212 (43.80)            |
| 4-8                              | 255 (52.69)            |
| >8                               | 17 (3.51)              |
| Borrmann type                    |                        |
| Fungating                        | 210 (43.39)            |
| Infiltrative                     | 91 (18.80)             |
| Ulcerative                       | 183 (37.81)            |
| Histological subtypes            |                        |
| Moderately/well-differentiated adenocarcinomas | 383 (79.13) |
| Poorly differentiated adenocarcinoma | 43 (8.89)     |
| Mucinous adenocarcinoma          | 49 (10.12)             |
| Signet-ring cell carcinoma       | 9 (1.86)               |
| Depth of invasion                |                        |
| Mucosa and submucosa             | 24 (4.96)              |
| Muscular coat                    | 33 (6.82)              |
| Full-thickness                   | 243 (50.21)            |
| Beyond serosa                    | 184 (38.02)            |
| Dukes' stage                     |                        |
| Dukes' A                         | 58 (11.98)             |
| Dukes' B                         | 189 (39.05)            |
| Dukes' C                         | 201 (41.53)            |
| Dukes' D                         | 36 (7.44)              |
| Distant metastasis               |                        |
| Positive                         | 40 (8.26)              |

**Table I. Clinical and pathological characteristics from patients with colon cancer.**

| Characteristics                  | Number of patients (%) |
|----------------------------------|------------------------|
| Gender                           |                        |
| Male                             | 296 (61.16)            |
| Female                           | 188 (38.84)            |
| Age, years                       |                        |
| <40                              | 63 (13.02)             |
| 40-60                            | 226 (46.69)            |
| >60                              | 195 (40.29)            |
| Time course of disease, months   |                        |
| <1                               | 96 (19.83)             |
| 1-3                              | 152 (31.40)            |
| 3-6                              | 65 (13.43)             |
| 6-12                             | 75 (15.50)             |
| ≥12                              | 96 (19.84)             |
| Tumor location                   |                        |
| Left hemicolon                   | 245 (50.62)            |
| Colon transversum                | 50 (10.33)             |
| Right hemicolon                  | 189 (39.05)            |
| Surgery                          |                        |
| Radical surgery                  | 403 (83.26)            |
| Palliative surgery               | 81 (16.74)             |
| Perioperative blood transfusion, ml|                      |
| 0                                | 295 (60.95)            |
| ≤400                             | 100 (20.66)            |
| 400-800                          | 89 (18.39)             |
| Tumor size, cm                   |                        |
| ≤4                               | 212 (43.80)            |
| 4-8                              | 255 (52.69)            |
| >8                               | 17 (3.51)              |
| Borrmann type                    |                        |
| Fungating                        | 210 (43.39)            |
| Infiltrative                     | 91 (18.80)             |
| Ulcerative                       | 183 (37.81)            |
| Histological subtypes            |                        |
| Moderately/well-differentiated adenocarcinomas | 383 (79.13) |
| Poorly differentiated adenocarcinoma | 43 (8.89)     |
| Mucinous adenocarcinoma          | 49 (10.12)             |
| Signet-ring cell carcinoma       | 9 (1.86)               |
| Depth of invasion                |                        |
| Mucosa and submucosa             | 24 (4.96)              |
| Muscular coat                    | 33 (6.82)              |
| Full-thickness                   | 243 (50.21)            |
| Beyond serosa                    | 184 (38.02)            |
| Dukes' stage                     |                        |
| Dukes' A                         | 58 (11.98)             |
| Dukes' B                         | 189 (39.05)            |
| Dukes' C                         | 201 (41.53)            |
| Dukes' D                         | 36 (7.44)              |
| Distant metastasis               |                        |
| Positive                         | 40 (8.26)              |

**Table I. Continued.**

| Characteristics                  | Number of patients (%) |
|----------------------------------|------------------------|
| Lymph node metastasis           |                        |
| Positive                         | 228 (47.11)            |
| Negative                         | 256 (52.89)            |
| p53 status                       |                        |
| Positive                         | 253 (52.27)            |
| Negative                         | 231 (47.73)            |
location, LN metastasis, distant metastasis, Dukes' stage and p53 expression levels were identified as independent factors that may influence the survival rate of patients with colon cancer following surgery (P<0.05; Table IV; Fig. 1).

**Discussion**

The present study enrolled 484 patients with primary colon cancer that had radical and palliative surgery and complete follow-up data was available. The clinicopathological features and colon cancer-associated prognostic factors were investigated to provide a reliable theoretical understanding of influencing factors in the prognosis of colon cancer, based on long-term follow-up data that was applicable to the patients in the geographical location of the present study. There were significant differences in p53 expression levels in various categories, including age distribution, disease course, tumor location, tumor size, depth of invasion, Dukes' stage, distant

| Clinical pathology index | p53 expression status | Positive | Negative | Positive rate, % | $\chi^2$ | P-value |
|--------------------------|-----------------------|----------|----------|------------------|---------|---------|
| Gender                   |                       |          |          |                  |         |         |
| Male                     |                       | 156      | 140      | 52.70            | 0.056   | 0.812   |
| Female                   |                       | 97       | 91       | 51.59            |         |         |
| Age, years               |                       |          |          |                  | 27.241  | <0.001  |
| <40                      |                       | 28       | 35       | 44.44            |         |         |
| 40-60                    |                       | 95       | 131      | 42.04            |         |         |
| >60                      |                       | 130      | 65       | 66.51            |         |         |
| Time course of disease, months |               |          |          |                  | 11.644  | 0.020   |
| <1                       |                       | 50       | 46       | 52.08            |         |         |
| 1-3                      |                       | 92       | 60       | 59.21            |         |         |
| 3-6                      |                       | 23       | 42       | 35.38            |         |         |
| 6-12                     |                       | 39       | 36       | 52.00            |         |         |
| ≥12                      |                       | 49       | 47       | 51.04            |         |         |
| Tumor site               |                       |          |          |                  | 12.352  | 0.002   |
| Left hemicolon           |                       | 147      | 98       | 60.00            |         |         |
| Colon transversum        |                       | 20       | 30       | 40.00            |         |         |
| Right hemicolon          |                       | 86       | 103      | 45.5             |         |         |
| Tumor size, cm           |                       |          |          |                  | 29.932  | <0.001  |
| ≤4                       |                       | 81       | 131      | 38.21            |         |         |
| 4-8                      |                       | 161      | 94       | 63.14            |         |         |
| >8                       |                       | 11       | 6        | 64.71            |         |         |
| Borrmann type            |                       |          |          |                  | 4.294   | 0.117   |
| Fungating                |                       | 102      | 108      | 48.57            |         |         |
| Infiltrative             |                       | 56       | 35       | 61.54            |         |         |
| Ulcerative               |                       | 95       | 88       | 51.91            |         |         |
| Histological subtypes    |                       |          |          |                  | 9.421   | 0.024   |
| Moderately/well-differentiated adenocarcinomas |   | 187      | 196      | 48.83            |         |         |
| Poorly differentiated adenocarcinoma |          | 30       | 13       | 69.77            |         |         |
| Mucinous adenocarcinoma  |                       | 30       | 19       | 61.22            |         |         |
| Signet-ring cell carcinoma |                   | 6        | 3        | 66.67            |         |         |
| Distant metastasis       |                       |          |          |                  | 4.053   | 0.044   |
| Positive                 |                       | 27       | 13       | 67.50            |         |         |
| Negative                 |                       | 226      | 218      | 50.90            |         |         |
| Lymph node metastasis    |                       |          |          |                  | 35.801  | <0.001  |
| Positive                 |                       | 152      | 76       | 66.67            |         |         |
| Negative                 |                       | 101      | 155      | 39.45            |         |         |
| Dukes' stage             |                       |          |          |                  | 41.643  | <0.001  |
| Dukes' A                 |                       | 17       | 41       | 29.31            |         |         |

Table II. The association of p53 expression levels with clinicopathological characteristics in patients with colon cancer.
Table III. Univariate analysis of associations between clinicopathological characteristics and follow-up data in patients with colon cancer.

| Characteristics                          | Number of patients (%) | Average length of survival, months | 10-year survival rate | P-value |
|------------------------------------------|------------------------|-----------------------------------|-----------------------|---------|
| Gender                                   |                        |                                   |                       |         |
| Male                                     | 296 (61.16)            | 79.47±3.37                        | 49.66                 | 0.162   |
| Female                                   | 188 (38.84)            | 79.87±3.51                        | 56.38                 |         |
| Age, years                               |                        |                                   |                       |         |
| <40                                      | 63 (13.02)             | 80.96±4.68                        | 50.79                 | <0.001  |
| 40-60                                    | 226 (46.69)            | 79.39±5.97                        | 63.27                 |         |
| >60                                      | 195 (40.29)            | 66.41±4.02                        | 40.00                 |         |
| Time course of disease, month            |                        |                                   |                       | 0.039   |
| <1                                       | 96 (19.83)             | 80.16±2.85                        | 48.96                 |         |
| 1-3                                      | 152 (31.40)            | 77.88±3.53                        | 45.39                 |         |
| 3-6                                      | 65 (13.43)             | 80.56±3.42                        | 56.92                 |         |
| 6-12                                     | 75 (15.50)             | 78.47±3.43                        | 66.67                 |         |
| ≥12                                      | 96 (19.83)             | 80.12±4.01                        | 52.08                 |         |
| Tumor location                           |                        |                                   |                       | 0.006   |
| Left hemicolon                           | 245 (50.62)            | 74.96±5.21                        | 46.12                 |         |
| Colon transversum                        | 50 (10.33)             | 85.37±5.67                        | 64.00                 |         |
| Right hemicolon                          | 189 (39.05)            | 84.69±3.68                        | 59.26                 |         |
| Surgery                                  |                        |                                   |                       | <0.001  |
| Radical surgery                          | 403 (83.26)            | 94.18±3.68                        | 60.54                 |         |
| Palliative surgery                       | 81 (16.74)             | 26.08±2.82                        | 11.11                 |         |
| Perioperative blood transfusion, ml      |                        |                                   |                       | 0.042   |
| 0                                        | 295 (60.95)            | 81.23±4.66                        | 53.89                 |         |
| ≤400                                     | 100 (20.66)            | 78.50±6.72                        | 55.00                 |         |
| 400-800                                  | 89 (18.39)             | 66.18±8.06                        | 40.44                 |         |
| Tumor size, cm                           |                        |                                   |                       | 0.024   |
| ≤4                                       | 212 (43.80)            | 98.05±7.09                        | 70.75                 |         |
| 4-8                                      | 255 (52.69)            | 78.50±4.90                        | 38.04                 |         |
| >8                                       | 17 (3.51)              | 66.18±7.07                        | 35.29                 |         |
| Borrmann type                            |                        |                                   |                       | 0.516   |
| Fungating                                | 210 (43.39)            | 84.59±5.51                        | 60.23                 |         |
| Infiltrative                             | 91 (18.80)             | 67.15±3.65                        | 49.45                 |         |
| Ulcerative                               | 183 (37.81)            | 79.36±3.05                        | 50.27                 |         |
| Histological subtypes                    |                        |                                   |                       | <0.001  |
| Moderately/well-differentiated adenocarcinomas | 383 (79.13)         | 97.15±6.98                        | 56.4                  |         |
| Poorly differentiated adenocarcinoma      | 43 (8.89)              | 66.70±5.70                        | 30.77                 |         |
| Mucinous adenocarcinoma                  | 49 (10.12)             | 86.74±5.98                        | 48.82                 |         |
| Signet-ring cell carcinoma               | 9 (1.86)               | 22.61±5.22                        | 0.00                  |         |
| Depth of invasion                        |                        |                                   |                       | <0.001  |
| Mucosa and submucosa                     | 24 (4.96)              | 116.72±5.82                       | 91.67                 |         |
| Muscular coat/muscularis                 | 33 (6.82)              | 106.21±4.65                       | 84.85                 |         |
| Full-thickness                           | 243 (50.21)            | 80.33±4.51                        | 60.90                 |         |
| Beyond serosa                            | 184 (38.02)            | 39.59±3.62                        | 29.89                 |         |
| Dukes' stage                             |                        |                                   |                       | <0.001  |
| Dukes' A                                 | 58 (11.98)             | 116.44±2.84                       | 93.1                  |         |
| Dukes' B                                 | 189 (39.05)            | 101.86±3.04                       | 64.55                 |         |
| Dukes' C                                 | 201 (41.53)            | 66.83±7.13                        | 36.82                 |         |
| Dukes' D                                 | 36 (7.44)              | 29.13±3.98                        | 8.33                  |         |
| Distant metastasis                       |                        |                                   |                       | 0.004   |
| Positive                                 | 40 (8.26)              | 39.59±3.29                        | 12.50                 |         |
metastasis and LN metastasis, which suggests that the loss of p53 expression is associated with aggressive clinicopathological features in patients with colon cancer. In addition, the age, surgery type, histological subtypes, tumor size, tumor location, LN metastasis, distant metastasis, Dukes' stage and p53 expression status were independent factors that influenced the survival rate of patients with colon cancer following surgery.

A previous retrospective tumor microarray study also established that p53 may be a potential biological diagnostic marker (29) and p53 status has been demonstrated to be associated with colon cancer prognosis (15). However, a previous study was not able to demonstrate a significant association between p53 expression levels and clinical outcomes in patients with colon cancer (35). Notably, the association between p53 expression levels and clinicopathological data in patients with colon cancer was evaluated in a previous study, and the results suggested that right-sided colon tumors may develop in a p53-independent manner and, therefore, p53 status in cancer cells has prognostic value only for left-sided colorectal tumors (36). However, the present study indicated that the loss of p53 expression in colon cancer may be a predictor of a more aggressive tumor phenotype and other clinicopathological characteristics may also require consideration in conjunction with p53 status to design an effective follow-up strategy to improve patient survival rate.

Table III. Continued.

| Characteristics          | Number of patients (%) | Average length of survival, months | 10-year survival rate | P-value |
|--------------------------|------------------------|-----------------------------------|-----------------------|---------|
| Negative                 | 444 (91.74)            | 87.58±4.96                        | 55.85                 | <0.001  |
| Lymph node metastasis    |                        |                                   |                       |         |
| Positive                 | 228 (47.11)            | 44.59±4.74                        | 33.77                 |         |
| Negative                 | 256 (52.89)            | 86.74±5.06                        | 68.75                 |         |
| p53 status               |                        |                                   |                       | <0.001  |
| Positive                 | 253 (52.27)            | 37.61±2.61                        | 30.83                 |         |
| Negative                 | 231 (47.73)            | 85.18±3.68                        | 75.76                 |         |

Table IV. Multivariate analysis for overall survival rate in patients with different prognostic variations of colon cancer.

| Characteristic         | B       | SE      | Wald χ² | P-value | EXP(B) | 95% CI          |
|------------------------|---------|---------|---------|---------|--------|-----------------|
| Age                    | 0.022   | 0.055   | 0.158   | 0.011   | 1.522  | 1.018-1.838     |
| Course of disease      | -0.320  | 0.286   | 1.444   | 0.023   | 0.726  | 0.431-1.224     |
| Surgery                | 0.789   | 0.257   | 9.424   | 0.002   | 2.200  | 1.330-3.640     |
| Blood transfusion      | -0.028  | 0.091   | 0.082   | 0.775   | 0.974  | 0.818-1.164     |
| Pathological type      | 0.157   | 0.052   | 9.026   | 0.003   | 1.170  | 1.056-1.297     |
| Tumor diameter         | 0.149   | 0.063   | 5.487   | 0.019   | 1.160  | 1.025-1.314     |
| Tumor site             | 0.087   | 0.035   | 6.022   | 0.014   | 1.091  | 1.018-1.169     |
| Lymph node metastasis  | 0.406   | 0.072   | 31.607  | <0.001  | 1.501  | 1.303-1.729     |
| Distant metastasis     | 0.286   | 0.087   | 10.891  | 0.001   | 1.332  | 1.123-1.579     |
| Dukes' stage           | 0.830   | 0.159   | 27.393  | <0.001  | 2.293  | 1.680-3.128     |
| p53 expression         | 0.864   | 0.400   | 27.939  | 0.031   | 2.372  | 1.680-3.128     |

B, coefficient for the constant; SE, standard error; EXP(B), exponentiation of the coefficient constant; CI, confidence interval.
of metastases is an independent prognostic factor for OS (41,43). Pulmonary metastasis has been demonstrated to occur in patients with low stage colon tumors and the survival rate following thoracotomy is dependent on the number of metastases (44). Patients with unilateral metastasis and Dukes’ A primary tumor type exhibit the highest increase in survival rate following the resection of pulmonary metastasis from CRC (45). Furthermore, LN metastasis is a poor prognostic factor for colon cancer and the number of involved LNs has been implicated in the survival rate of patients with stage II and stage III colon cancer following surgical resection, which is consistent with the number of involved LNs providing an indicator of the care that the patient with colon cancer requires (17,46). Concordant with this, LN yield (LNY) is an independent prognostic factor in colon cancer and ≥12 LNs in the resected specimen obtained from surgery is the current recommended standard, regardless of age or disease site, and LNY is increased in right-sided colon cancer and reduces with age (47). It has been established using multivariate analysis that LN micrometastasis and lymphatic invasion are independent prognostic factors for CRC (48). The histological pattern may also be associated with an increased survival rate and patients with grade I moderately-differentiated tumors exhibit the highest rate of survival (41,42). Several clinicopathological factors were not previously identified to be effective independent predictors of survival rate in patients with colon cancer, including Dukes’ stage, T stage, number of resected nodes and vascular or lymphatic invasion (49).

In conclusion, the results of the present study revealed that p53 expression levels are associated with an increased survival rate and patients with grade I moderately-differentiated tumors exhibit the highest rate of survival (41,42). Several clinicopathological factors were not previously identified to be effective independent predictors of survival rate in patients with colon cancer, including Dukes’ stage, T stage, number of resected nodes and vascular or lymphatic invasion (49).

Acknowledgements

The authors would like to acknowledge the helpful comments on this study received from the reviewers.
References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Merika E, Saif MW, Katz A, Syrigos K and Morse M: Review. Colon cancer vaccines: An update. In vivo 24: 607-628, 2010.
3. Lee DH, Keum N and Giovannucci EL: Colorectal cancer epidemiology in the nurses’ health study. Am J Public Health 106: 1599-1607, 2016.
4. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global patterns and trends in colorectal cancer incidence and mortality. Gut pii: gutjnl-2015-310912, 2016 (Epub of print).
5. Stein A, Atanackovic D and Bokemeyer C: Current standards and new trends in the primary treatment of colorectal cancer. Eur J Cancer 47 (Suppl 3): S312-S314, 2011.
6. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet 375: 1030-1047, 2010.
7. Desch CE, Benson AB III, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Ptister DG, Virgo KS and Petrelli NJ: American Society of Clinical Oncology: Colorectal cancer surveillance: 2005 update of an American society of clinical oncology practice guideline. J Clin Oncol 23: 8512-8519, 2005.
8. Engstrom PF, Arnottepi JJ, Benson AB III, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, et al: NCCN clinical practice guidelines in oncology: Colon cancer. J Natl Compr Canc Netw 7: 778-831, 2009.
9. Jeffery M, Be E and Hider PN: Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev CD002200: 2007.
10. Tjandra J and Chan MK: Follow-up after curative resection of colorectal cancer: A meta-analysis. Dis Colon Rectum 50: 1783-1799, 2007.
11. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummins B, McLeod R, Zuraw L and Zwaal C; Gastrointestinal Cancer Oncology Practice Guideline Task Force: Recommendations for follow-up of patients with curatively resected colorectal cancer: A practice guideline. BMC Cancer 3: 26, 2003.
12. Longo WE, Virgo KS, Johnson FE, Oprian CA, Vernava AM, Wade TP, Phelan MA, Henderson WG, Daley J and Khuri SF: Risk factors for morbidity and mortality after colectomy for colon cancer. Dis Colon Rectum 43: 83-91, 2000.
13. Debarroos M and Steele SR: Perioperative protocols in colorectal surgery. Clinics Colon Rectal Surg 26: 139-145, 2013.
14. Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64: 104-117, 2014.
15. Nasif WA, Lotfy M, El-Sayed IH, El-Kenawy A, Saraga E, Pampallona S, Bosman FT and Givel JC: Colon cancer vaccines: An update. In vivo 24: 607-628, 2010.
16. Nakagawa T, Ueki T, Satriano R, Haller DG, Tsujii JJ and Finan PJ: Prognostic factors for survival after curative resection of Dukes’ B colorectal cancer. Colorectal Dis 13: 1390-1394, 2011.
17. Bouzoures E, Cerozzi V, Benhattar J, Chaubert P, Saraga E, Pamplona S, Bosman FT and Givel JC: p53 and Ki-ras as prognostic factors for Dukes’ stage B colorectal cancer. Eur J Cancer 36: 1008-1015, 2000.
18. Allegra CQ, Paiak S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N and Wicand HS: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer. A national cancer institute-national surgical adjunctive treatment and bowel project collaborative study. J Clin Oncol 21: 241-250, 2003.
19. Lane DP: Cancer. p53, guardian of the genome. Nature 358: 15-16, 1992.
20. Bernier G, Vincenzi B, Santini D, Verzi A, Tonini G, Vetran T and Rabitti C: Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinicopathological features in colon cancer. Cancer Lett 208: 227-234, 2004.
21. Figueredo A, Rumble RB, Maroun J, Tian Y and Lin TY: Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 25: 1674-1680, 2010.
22. El-Serafi MM, Bahnassy AA, Ali NM, Eid SM, Kamel MM, Abdel-Hamid NA and Zekri AR: The expression value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer. Cancer 116: 4954-4964, 2010.
23. Liang JT, Huang KC, Jeng YM, Lee PH, Lai HS and Hsu HC: Microvessel density, cycle-oxygenase 2 expression, K-ras mutation and p53 overexpression in colon cancer. Br J Surg 91: 355-360, 2004.
24. Resnick MB, Routhier J, Konkin T, Sabo E and Pricolo VE: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: A tissue microarray study. Clin Cancer Res 10: 3069-3075, 2010.
25. Nasiif WA, El-Emshaty HM, Tabll A, Elmasry SA, Attallah AM and Gad Elhak NA: Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma. Hepatogastroenterology 51: 1001-1006, 2004.
26. Saracqueta AF, Forte G, Corver WE, de Miranda NF, Ruano D, van Eijk O, Oosting J, Tollenaar RA, van Wezel T and Morreau H: Integral analysis of p53 and its value as prognostic factor in colon cancer. BMC Cancer 13: 277, 2013.
27. Allegra CQ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O’Connell MJ, Levitt R, et al: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20: 1735-1743, 2002.
28. Li M and Gu J: Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol 11: 4685-4688, 2005.
29. Dilmeć F, Özgünöl A, Akkafa F, Uzunkoy A and Kuilenburg ABPV: Determination of Apal and TaqI Polymorphisms of VDR gene in a group of Turkish patients with colorectal cancer. Hernia 19: 2128-21263, 2005.
30. Veruttipong D, Soliman AS, Gilbert SF, Blachley TS, Hsia CT, Satriano R, Haller DG, Eiff SM, Kamel MM, Sikorski MM, Huang GL, Guo HO, Guo CC, Li HY, Ye S, Ling S, Jiang L, Tian Y and Lin TY: Circulating miR-221 directly ampliﬁed from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 25: 1674-1680, 2010.
31. El-Serafi MM, Bahnassy AA, Ali NM, Eid SM, Kamel MM, Abdel-Hamid NA and Zekri AR: The expression value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer. Cancer 116: 4954-4964, 2010.
32. Liang JT, Huang KC, Jeng YM, Lee PH, Lai HS and Hsu HC: Microvessel density, cycle-oxygenase 2 expression, K-ras mutation and p53 overexpression in colon cancer. Br J Surg 91: 355-360, 2004.
33. Resnick MB, Routhier J, Konkin T, Sabo E and Pricolo VE: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: A tissue microarray study. Clin Cancer Res 10: 3069-3075, 2004.
34. Nasiif WA, El-Emshaty HM, Tabll A, Elmasry SA, Attallah AM and Gad Elhak NA: Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma. Hepatogastroenterology 51: 1001-1006, 2004.
35. Saracqueta AF, Forte G, Corver WE, de Miranda NF, Ruano D, van Eijk O, Oosting J, Tollenaar RA, van Wezel T and Morreau H: Integral analysis of p53 and its value as prognostic factor in colon cancer. BMC Cancer 13: 277, 2013.
36. Allegra CQ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O’Connell MJ, Levitt R, et al: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20: 1735-1743, 2002.
37. Li M and Gu J: Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol 11: 4685-4688, 2005.
42. Deliu IC, Georgescu EF and Bezna MC: Analysis of prognostic factors in colorectal carcinoma. Rev Med Chir Soc Med Nat Iasi 118: 808-816, 2014.

43. Okuno K: Surgical treatment for digestive cancer. Current issues-colon cancer. Dig Surg 24: 108-114, 2007.

44. Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, Nakagawa K, Fukuhara K, Maeda H, Takeda S, et al: Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 78: 238-244, 2004.

45. Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, Nakagawa K, Fukuhara K, Maeda H, Takeda S, et al: Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 78: 238-244, 2004.

46. Kobayashi H, West NP, Takahashi K, Perrakis A, Weber K, Hohenberger W, Quirke P and Sugihara K: Quality of surgery for stage III colon cancer: Comparison between England, Germany, and Japan. Ann Surg Oncol 21 (Suppl 3): S398-S404, 2014.

47. Ahmadi O, Stringer MD, Black MA and McCall JL: Influence of age and site of disease on lymph node yield in colorectal cancer. N Z Med J 127: 31-40, 2014.

48. Ueda Y, Yasuda K, Inomata M, Shiraiishi N, Yokoyama S and Kitano S: Biological predictors of survival in stage II colorectal cancer. Mol Clin Oncol 1: 643-648, 2013.

49. Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V, Romano C, Vollaro M, Agostini B, Pignatelli C and De Vita F: Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis Colon Rectum 47: 1904-1914, 2004.